ProCyte seeks US clearance for wound care product:
This article was originally published in Clinica
Executive Summary
ProCyte (US) has filed for US FDA clearance of its Iamin gel wound dressing as a Class I device. Intended for use as a hydrogel, Iamin will compete in a market estimated to be worth $300 million this year. By the end of the decade the US wound management market is projected to reach $2,900 million.